Zoetis Inc. (NYSE:ZTS) Shares Bought by Integral Investment Advisors Inc.

Integral Investment Advisors Inc. raised its stake in Zoetis Inc. (NYSE:ZTS) by 8.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,992 shares of the company’s stock after acquiring an additional 244 shares during the quarter. Integral Investment Advisors Inc.’s holdings in Zoetis were worth $487,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Fisher Funds Management LTD acquired a new position in shares of Zoetis in the fourth quarter worth $66,123,000. Pinnacle Financial Partners Inc increased its stake in Zoetis by 0.6% in the fourth quarter. Pinnacle Financial Partners Inc now owns 46,136 shares of the company’s stock valued at $7,520,000 after purchasing an additional 271 shares during the last quarter. Sigma Planning Corp increased its stake in Zoetis by 4.3% in the fourth quarter. Sigma Planning Corp now owns 3,367 shares of the company’s stock valued at $549,000 after purchasing an additional 140 shares during the last quarter. Oxbow Advisors LLC increased its stake in Zoetis by 768.1% in the fourth quarter. Oxbow Advisors LLC now owns 27,284 shares of the company’s stock valued at $4,445,000 after purchasing an additional 24,141 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its stake in Zoetis by 6.6% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock valued at $170,000 after purchasing an additional 65 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $160.39 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The firm has a market cap of $71.82 billion, a P/E ratio of 29.32, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The stock has a 50-day simple moving average of $166.51 and a 200-day simple moving average of $177.99.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Piper Sandler dropped their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $215.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.